Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Monday, March 10th. Analysts expect Cadrenal Therapeutics to post earnings of ($1.71) per share for the quarter.
Cadrenal Therapeutics Stock Performance
NASDAQ:CVKD opened at $16.85 on Friday. Cadrenal Therapeutics has a 52 week low of $5.40 and a 52 week high of $22.90. The firm has a market cap of $30.04 million, a price-to-earnings ratio of -2.52 and a beta of 1.40. The firm’s 50-day simple moving average is $18.07 and its 200 day simple moving average is $14.74.
Analysts Set New Price Targets
Separately, HC Wainwright raised their target price on shares of Cadrenal Therapeutics from $3.00 to $32.00 and gave the company a “buy” rating in a report on Monday, November 11th.
Cadrenal Therapeutics Company Profile
Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
See Also
- Five stocks we like better than Cadrenal Therapeutics
- The Role Economic Reports Play in a Successful Investment Strategy
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 Stocks to Buy While Others Stay on the Sidelines
- How to start investing in penny stocks
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
